\
Advanced Dual Diabetes Therapy
Combining Metformin and Vildagliptin for optimal Type 2 diabetes management
Dual Mechanism Action
Combines DPP-4 inhibition with insulin sensitization for comprehensive glucose control through multiple pathways.
Cardiovascular Safety
Proven cardiovascular safety with potential benefits for heart health in diabetic patients.
Convenient Dosing
Fixed-dose combination therapy improving patient compliance and treatment adherence.
Patient Compliance
Convenient dosing regimens and extended-release formulations designed for improved patient adherence.
Quality Assured
Manufactured under strict WHO-GMP guidelines ensuring highest quality standards and safety profiles.
Advanced Dual Diabetes Technology
Krevild combines Metformin and Vildagliptin through advanced pharmaceutical technology to deliver optimal diabetes management with enhanced patient compliance.
DPP-4 Inhibition
Vildagliptin blocks DPP-4 enzyme increasing incretin hormones for glucose-dependent insulin secretion.
Insulin Sensitization
Metformin improves insulin sensitivity and reduces hepatic glucose production for enhanced glucose control.
Complementary Action
Dual mechanisms provide comprehensive diabetes management with minimal risk of hypoglycemia.
Key Active Ingredients
Metformin HCl
Biguanide - Insulin SensitizerVildagliptin
DPP-4 InhibitorFixed Dose Combination
Dual Mechanism ActionClinical Efficacy
Significant HbA1c reduction with dual mechanism action for comprehensive Type 2 diabetes management
Type 2 Diabetes Mellitus Benefits of Krevild
In Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a chronic condition characterized by insulin resistance and progressive pancreatic beta-cell dysfunction, leading to persistent hyperglycemia and long-term complications.
How Krevild (Metformin 500mg + Vildagliptin 50mg) Works:
- Metformin: Reduces hepatic glucose production and improves peripheral insulin sensitivity
- Vildagliptin: Inhibits DPP-4 enzyme, increasing incretin hormone levels (GLP-1 and GIP)
- Promotes glucose-dependent insulin secretion
- Reduces inappropriate glucagon release
- Improves overall glycemic control with minimal hypoglycemia risk
This dual combination provides comprehensive diabetes management through complementary mechanisms of action.
Dual Mechanism Action
Metformin Action
Reduces glucose production, improves insulin sensitivityVildagliptin Action
DPP-4 inhibition, increases incretin hormonesGlucose Control
Superior glycemic control with dual benefitsKrevild Product Portfolio
Comprehensive anti-viral solutions tailored for different patient needs and treatment protocols
Proven Anti-Viral Benefits
Viral Clearance
High viral clearance rate in clinical studies with significant reduction in viral load
Recovery Rate
Accelerated recovery with reduced symptom duration and faster return to normal health
Safety Profile
Excellent safety and tolerability profile with minimal adverse effects
Patient Satisfaction
High patient satisfaction with improved quality of life and treatment outcomes